Showing results (81-90 of 89) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Cancer Prevention Research (Philadelphia, Pa.)|March 2, 2021
Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic NeoplasiaFrank A Sinicrope, Thomas R Viggiano, Navtej S Buttar, et al.Gastroenterology|July 17, 2012
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagusGary W Falk, Navtej S Buttar, Nathan R Foster, et al.Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2026
Randomized, Double-blind, Placebo-controlled Trial of Meriva® (curcuminoids) as a Candidate Chemoprevention Agent for Gastric CarcinogenesisMaria Gonzalez-Pons, Ricardo L Dominguez, Eleazar E Montalvan-Sanchez, et al.Cancer Prevention Research (Philadelphia, Pa.)|September 6, 2019
Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal NeoplasmsFrank A Sinicrope, Pruthvi R Velamala, Louis M Wong Kee Song, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2019
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell CarcinomaDaniel J Ma, Katharine A Price, Eric J Moore, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal JunctionMojun Zhu, Chunhua Chen, Nathan R Foster, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal AdenomaRobert E Schoen, Lisa A Boardman, Marcia Cruz-Correa, et al.JAMA Otolaryngology-- Head & Neck Surgery|May 22, 2025
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical TrialDavid M Routman, Kathryn M Van Abel, Katharine A Price, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.Pageof 9